Coherus BioSciences (NASDAQ:CHRS) reported quarterly losses of $(0.60) per share which beat the analyst consensus estimate of $(0.84) by 28.57 percent. This is a 30.43 percent decrease over losses of $(0.46) per share from the same period last year. The company reported quarterly sales of $45.35 million which missed the analyst consensus estimate of $47.68 million by 4.88 percent. This is a 38.19 percent decrease over sales of $73.37 million the same period last year.
Castellum, Inc. Announces The Award Of NAVAIR Contract For ALRE V2MMS
Castellum, Inc. (NYSE-American: CTM) announces the award of the NAVAIR Aircraft Launch & Recovery Equipment (ALRE) V2 Maintenance Management System (V2MMS) contract to its subsidiary Specialty Systems, Inc. (SSI).
